A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Phase 1
60
about 6.9 years
18–60
1 site in MO
What this study is about
This trial is testing a treatment called P-CD19CD20-ALLO1 for people with multiple sclerosis. The goal is to see how safe and well the treatment works, including how it affects cells in the body and its effects on the disease.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive P-CD19CD20-ALLO1 Cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Number of Participants With Adverse Events (AEs), Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1
Neurology